Average Weight Loss and A1C Improvements at 12 Months

The SURPASS clinical trial program studied Mounjaro in patients with type 2 diabetes, while the SURMOUNT trials focused on obesity without diabetes. Here is what the data shows at approximately one year:

• For type 2 diabetes (SURPASS trials): Patients on Mounjaro 15 mg lost an average of 12.4 kg (27.3 lbs) over 40 to 52 weeks. A1C reductions averaged 2.0% to 2.3%, bringing many patients below the 7.0% target .
• For obesity without diabetes (SURMOUNT-1): Patients on 15 mg lost an average of 22.5% of body weight (roughly 52 lbs from a starting weight of 231 lbs) over 72 weeks .

These numbers make Mounjaro one of the most effective prescription weight loss options currently available.

Month-by-Month Timeline on Mounjaro

• Month 1 (2.5 mg): Titration phase. Weight loss is modest, typically 2 to 5 pounds. Many patients notice reduced hunger and some GI adjustment (nausea, bloating). Blood sugar improvements may begin within the first few weeks for diabetic patients.
• Month 2 (5.0 mg): Appetite suppression strengthens. Cumulative weight loss of 5 to 10 pounds. Patients with diabetes often see their fasting glucose numbers drop noticeably.
• Months 3 to 4 (7.5 mg): This is when many patients describe a "turning point." Cumulative loss of 12 to 20 pounds. Food cravings drop, portion sizes shrink naturally, and energy levels often improve.
• Months 5 to 7 (10 mg to 15 mg): Rapid and visible progress. Cumulative loss of 20 to 35 pounds. Waist measurements decrease. Lab work typically shows meaningful improvements in A1C, triglycerides, and blood pressure.
• Months 8 to 10: Weight loss continues but the rate begins to moderate. Cumulative loss of 28 to 45 pounds. The body is adjusting to a lower weight.
• Months 11 to 12: Many patients approach their plateau on their current dose. Total loss of 25 to 55 pounds depending on dose, starting weight, and lifestyle adherence.

Side Effects Over the First Year

Knowing what to expect helps you stay on track:

• GI symptoms (months 1 to 3): Nausea affects about 12% to 18% of patients at each dose level. Diarrhea and constipation are also common early on. These symptoms typically peak during dose increases and then subside within 1 to 2 weeks.
• Reduced appetite (ongoing): Most patients experience a sustained decrease in hunger. This is the primary therapeutic mechanism, not just a side effect.
• Injection site reactions: Occasional redness or swelling at the injection site. Usually mild and short-lived.
• Fatigue (months 1 to 4): Some patients report tiredness during caloric restriction. Adequate protein and hydration help.
• Gallbladder issues: Rapid weight loss increases the risk of gallstones. Report any right-sided abdominal pain to your doctor .

How Mounjaro Compares to Other GLP-1 Options at 1 Year

For context, here is how Mounjaro's 1-year outcomes stack up:

• Mounjaro 15 mg: 20% to 22% average body weight loss
• Wegovy (semaglutide 2.4 mg): 15% to 17% average body weight loss
• Ozempic (semaglutide 1.0 mg): 6% to 10% average body weight loss
• Liraglutide (Saxenda): 5% to 8% average body weight loss

Mounjaro's dual receptor mechanism appears to provide a meaningful advantage, particularly for patients who need to lose a larger percentage of their body weight .

Practical Tips for Your First Year

• Do not skip the titration: Mounjaro has five dose levels for a reason. Jumping ahead increases side effects without improving results.
• Load up on protein: Target 1.0 to 1.2 grams of protein per kilogram of body weight daily. Protein shakes can help if appetite is very low.
• Strength train 2 to 3 times weekly: Resistance exercise is the best defense against lean muscle loss during significant weight reduction.
• Keep a food journal: Tracking what you eat helps you make intentional choices when appetite is suppressed.
• Get labs done every 3 months: Monitor A1C, lipids, liver function, and kidney markers. Celebrate the improvements you see.
• Stay hydrated: Drink at least 64 ounces of water daily. Dehydration worsens constipation and fatigue.

Frequently Asked Questions

Is Mounjaro the same as Zepbound?

Both contain tirzepatide as the active ingredient. Mounjaro is approved for type 2 diabetes, while Zepbound is approved specifically for chronic weight management. The dosing and medication are identical, but the FDA indications and insurance coverage differ.

What if I reach my goal weight before 12 months?

Your provider may reduce your dose to a maintenance level rather than continuing at the highest dose. The goal is to find the lowest effective dose that maintains your results while minimizing side effects.

Can I drink alcohol while taking Mounjaro?

Moderate alcohol consumption is generally acceptable, but Mounjaro can intensify the effects of alcohol since it slows gastric emptying. Start with small amounts and see how you respond. Avoid high-calorie cocktails that work against your weight loss goals .

Will my insurance cover Mounjaro for weight loss?

Coverage depends on your plan and diagnosis. Mounjaro is more commonly covered for type 2 diabetes than for weight management alone. If weight loss is your primary goal, ask your provider about Zepbound or compounded options $1,000-$1,200/mo (brand).

How long should I plan to stay on Mounjaro?

Current evidence supports long-term use. The SURMOUNT-4 trial showed that patients who discontinued tirzepatide regained a significant portion of their lost weight within 12 months . Most providers recommend planning for ongoing treatment or a structured step-down approach.

Start Your Mounjaro Treatment with Expert Support

A year on Mounjaro can reshape your health in ways that go well beyond the number on the scale. To get the most from treatment, work with a provider who understands tirzepatide dosing, monitoring, and long-term planning. FormBlends connects you with licensed clinicians who specialize in GLP-1 and peptide therapy.

Book your clinical consultation today.